#Chek2
Ranked lollipop chart of CHEK2 median expression across human tissues from GTEx, with tissues listed on one axis and expression in TPM on a log scale, each lollipop extending above or below the cross-tissue median of 3.0 TPM.

#Chek2 #DnaDamageResponse #CheckpointKinase #GtexV8 #BulkRnaSeq
November 6, 2026 at 5:03 PM
Beyond BRCA: What really increases your breast cancer risk

The short answer: BRCA1 and BRCA2 are not the only genes that raise breast cancer risk. Research has identified several other inherited gene changes, including PALB2, ATM, CHEK2, BARD1, and RAD51D, that increase risk by varying amounts…
Beyond BRCA: What really increases your breast cancer risk
The short answer: BRCA1 and BRCA2 are not the only genes that raise breast cancer risk. Research has identified several other inherited gene changes, including PALB2, ATM, CHEK2, BARD1, and RAD51D, that increase risk by varying amounts [1]. Family history matters even when BRCA testing is negative. A 2026 study found that women who test negative for BRCA mutations still had a 25 percent lifetime risk if they had a family history of cancer [2]. And most breast cancers, about 80 percent, occur in women with no specific risk factors other than being female and getting older [5].
trenderhq.com
October 9, 2026 at 8:25 AM
“Ik dacht nog: laat het alsjeblieft bij mij stoppen”: Patrick (67) gaf kankergen door aan een van zijn kinderen

Toen Patrick (67) uit Westerlo borstkanker kreeg, dacht hij dat de ziekte alleen hém had getroffen. Tot genetisch onderzoek uitwees dat hij een erfelijke CHEK2-mutatie draagt....
“Ik dacht nog: laat het alsjeblieft bij mij stoppen”: Patrick (67) gaf kankergen door aan een van zijn kinderen
Toen Patrick (67) uit Westerlo borstkanker kreeg, dacht hij dat de ziekte alleen hém had getroffen. Tot genetisch onderzoek uitwees dat hij een erfelijke CHEK2-mutatie draagt. Tijdens de Week van erfe...
www.hln.be
September 28, 2026 at 12:47 PM
“Ik dacht: ben ik nu de eerste man in België met borstkanker?”, maar de klap kwam écht toen Patrick (67) ontdekte dat erfelijk gen de boosdoener was

Toen Patrick (67) uit Westerlo borstkanker kreeg, dacht hij dat de ziekte alleen hém had getroffen. Tot genetisch onderzoek uitwees dat hij een...
“Ik dacht nog: laat het alsjeblieft bij mij stoppen”: Patrick (67) gaf kankergen door aan een van zijn kinderen
Toen Patrick (67) uit Westerlo borstkanker kreeg, dacht hij dat de ziekte alleen hém had getroffen. Tot genetisch onderzoek uitwees dat hij een erfelijke CHEK2-mutatie draagt. Tijdens de Week van erfe...
www.hln.be
September 28, 2026 at 12:23 PM
Li-Fraumeni Syndrome Market Size Trends and Forecast by Application, Type, and Geography, Opportunity Analysis

"Global Li-Fraumeni Syndrome Market - Overview, Size, Share, Industry Trends and Opportunities Global Li-Fraumeni Syndrome Market, By Genes Type (CHEK2 and TP53), Therapy Type…
Li-Fraumeni Syndrome Market Size Trends and Forecast by Application, Type, and Geography, Opportunity Analysis
"Global Li-Fraumeni Syndrome Market - Overview, Size, Share, Industry Trends and Opportunities Global Li-Fraumeni Syndrome Market, By Genes Type (CHEK2 and TP53), Therapy Type (Chemotherapy, Radiation Therapy and Biological Therapy), Treatment (Medication and Surgery), Route of Administration (Oral and Injectable), End Users (Hospitals, Homecare, Specialty Clinics and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others), and Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of the Middle East and Africa) Industry Trends and Forecast to 2028…
databridgemarketresearch2.wordpress.com
March 10, 2025 at 10:34 AM
Li-Fraumeni Syndrome Market Opportunities and Strategies Size, Share, and Analysis

"Global Li-Fraumeni Syndrome Market - Industry Trends and Forecast to 2028 Global Li-Fraumeni Syndrome Market, By Genes Type (CHEK2 and TP53), Therapy Type (Chemotherapy, Radiation Therapy and Biological Therapy),…
Li-Fraumeni Syndrome Market Opportunities and Strategies Size, Share, and Analysis
"Global Li-Fraumeni Syndrome Market - Industry Trends and Forecast to 2028 Global Li-Fraumeni Syndrome Market, By Genes Type (CHEK2 and TP53), Therapy Type (Chemotherapy, Radiation Therapy and Biological Therapy), Treatment (Medication and Surgery), Route of Administration (Oral and Injectable), End Users (Hospitals, Homecare, Specialty Clinics and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others), and Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of the Middle East and Africa) Industry Trends and Forecast to 2028…
databridgemarketresearch2.wordpress.com
January 29, 2025 at 12:12 PM
Riesgo absoluto estimado de cáncer de mama asociado a variantes patogénicas
Se puede observar un mayor riesgo en los genes de alta penetrancia (BRCA1, BRCA2 y PALB2) respecto a los de penetrancia moderada (CHEK2, BARD1, ATM, RAD51C y RAD51D) https://buff.ly/3WcHmb8
January 10, 2025 at 9:54 AM
The international trial showed a 37% reduction in cancer growth risk, and even greater benefits for those with BRCA1 or BRCA2 mutations. While side effects were more common, the results support more exhaustive genetic testing and targeted treatment for those most at risk.
Prostate Cancer Patients Offered Fresh Hope by Promising New Drug Combination
New hope for advanced prostate cancer patients, with promising new drug combo that targets genes, such as BRCA1, BRCA2, CHEK2, and PALB2.
www.goodnewsnetwork.org
November 12, 2025 at 12:45 PM
Researchers found that adding niraparib, a targeted therapy, to standard hormone treatment significantly delayed cancer progression in patients with specific genetic mutations.
www.goodnewsnetwork.org/prostate-can...
Prostate Cancer Patients Offered Fresh Hope by Promising New Drug Combination
New hope for advanced prostate cancer patients, with promising new drug combo that targets genes, such as BRCA1, BRCA2, CHEK2, and PALB2.
www.goodnewsnetwork.org
November 12, 2025 at 12:43 PM
and c) wasn't the estrogen- breast cancer link only from one study 30 years ago that hasn't really been replicated? I have almost entirely fatty breasts while my aunts were both very dense. plus I believe they are homozygous for CHEK2.
January 18, 2026 at 8:05 PM
oh, oh AND another reason why nobody wanted to prescribe any HRT is because I am heterozygous for the CHEK2 gene and my two (*paternal*) aunts had breast cancer in their mid-60s. however a) my understanding is maternal breast cancer history is what informs cancer risk in women and b) I'm only 52...
January 18, 2026 at 8:03 PM
SCI member Allison Kurian found most lifestyle and reproductive factors don’t substantially raise # BreastCancer risk in BRCA1/2, ATM, CHEK2, or PALB2 mutation carriers—except possibly #HormoneTherapy, which may increase risk for ATM/CHEK2 carriers. aacrjournals.org/cancerrescom...
May 21, 2025 at 5:03 PM
Hier auch schon drei Jahre nicht mehr seit ich von CHEK2 weiß.. vermisse genau nüscht. Neu einiges Laster, Coke Zero. Glaub da kann ich genug davon trinken..
March 5, 2025 at 4:15 PM
5) Label-free phosphoproteomics identified PRKDC, CHEK2 and ATM as the top upstream kinases, forming a network linking Ca2+ oscillations to cell cycle and stress signaling.
October 10, 2025 at 9:40 PM
For more than half of PC patients, it’s driven by genetics. Mutations in BRCA1 and BRCA2, for instance, can increase the risk of prostate cancer. PC can also be driven by mutations in other DNA repair genes like ATM, CHEK2, and PALB2. Or by something else. www.nejm.org/doi/full/10.... 3/12
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer | NEJM
Inherited mutations in DNA-repair genes such as BRCA2 are associated with increased risks of lethal prostate cancer. Although the prevalence of germline mutations in DNA-repair genes among men with...
www.nejm.org
March 17, 2025 at 10:24 PM
Individuals with heterozygous CHEK2 variants had an increased risk for all cancer; breast, kidney, bladder, and prostate cancer; and lymphoid leukemia, although cancer risk was generally lower compared with phenotypically ascertained cohorts. ja.ma/3MFnlIj
Genomic Ascertainment of CHEK2-Related Cancer Predisposition
This case-control study evaluates the prevalence, cancer risk, and survival among adults with pathogenic or likely pathogenic germline variants in CHEK2.
ja.ma
December 16, 2025 at 2:20 PM
CHEK2 missense variants have been linked to breast and other cancers. The American Journal of Human Genetics' latest article addresses this problem through an exploration of structure-function relationships that provides variant classification for over 8,000 CHEK2 coding variants.

#ASHG
A missense variant effect map for the human tumor-suppressor protein CHK2
CHEK2 missense variants have been linked to breast and other cancers; however, ∼90% are classified as variants of uncertain significance. To explore sequence-structure-function relationships and to provide new evidence for clinical variant classification, we used a yeast-complementation assay to test over 8,000 CHEK2 coding variants.
www.cell.com
December 19, 2024 at 7:42 PM
You may not know about CHEK2 ... But you really should. Lacee Griffith explains: https://www.wbaltv.com/article/health-chek2-cancer-gene-mutations-brca-womans-doctor/69096515 
October 21, 2025 at 3:11 PM
Breast cancer risk for pathogenic variant carriers is substantially higher with a first-degree family history, and risk estimates vary by gene, family history, and other factors, guiding personalized screening and prevention decisions. ja.ma/4pPMpLB
December 22, 2025 at 12:00 PM
Breast cancer risk for pathogenic variant carriers is substantially higher with a first-degree family history, and risk estimates vary by gene, family history, and other factors, guiding personalized screening and prevention decisions.

ja.ma/4nIbzKZ
October 9, 2025 at 3:30 PM
Two sisters in their 20s are given cancer diagnoses at the same time mol.im/a/15310949 via @DailyMail
Two sisters in their 20s are given cancer diagnoses at the same time
Two North Carolina sisters in their 20s, part of a set of triplets, were diagnosed with breast cancer within months of each other after testing positive for the CHEK2 gene mutation.
mol.im
November 24, 2025 at 1:52 AM
The authors included RRIDs in their in Clinical Cancer Research paper! RRIDs improve reproducibility in scientific research. #OpenScience #reproducibility #OpenResearch
A Phase 2 Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
Read the full paper: A Phase 2 Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
doi.org
March 22, 2026 at 7:02 AM